Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Exp. Hematol., Oct;34(10):1360-76 (2006)
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Oncologist., Jan;12(1):99-106 (2007)
Music imagery for adults with acute leukemia in protective environments: a feasibility study.
Support Care Cancer., May;16(5):507-13 (2008)
Treating low-risk myelodysplastic syndromes in the community setting.
Clin Adv Hematol Oncol., Jun;6(6):418-20 (2008)
J Palliat Med., Sep;12(9):839-40 (2009)
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Bone Marrow Transplant., Aug;45(8):1300-8 (2010)
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Leuk. Res., Aug;35(8):1108-10 (2011)
Illness appraisal, religious coping, and psychological responses in men with advanced cancer.
Support Care Cancer., Aug;20(8):1719-28 (2012)
Malignant disorders of megakaryocytes.
Semin. Hematol., Jul;35(3):200-9 (1998)
Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
Blood., Oct;92(7):2450-60 (1998)
Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
Leuk. Res., Oct;24(10):871-5 (2000)
Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.
Leukemia., May;16(5):799-812 (2002)
Acute myeloid leukemia in adults.
Curr Treat Options Oncol., Apr;1(1):9-17 (2000)
Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.
Leuk. Res., Jan;28(1):49-52 (2004)
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Blood., Nov;116(20):4077-85 (2010)
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Leuk. Res., Jul;30(7):823-7 (2006)
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
Leukemia., Dec;25(12):1808-14 (2011)
Adult acute leukemia.
Curr Probl Cancer., 21(1):1-64 (1997)